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Assessment of faecal
microbial transfer in irritable
bowel syndrome with severe
bloating
We read with interest the work by
Halmos et al1 in which they describe the
effects of dietary FODMAP (Fermentable
Oligo-, Di- and Mono- saccharides And
Polyols) restriction in patients with IBS on
the intestinal microbiota. They showed
that low FODMAP intake was associated
with reduced total bacterial and lower
relative abundance of butyrate-producing
Clostridium cluster XIVa, changes that
are generally considered unfavourable.2
Therefore, they discourage long-term
dietary FODMAP restriction, a suggestion
also supported by the recent work of
McIntosh and colleagues who noticed
unfavourable changes in both microbiota
and metabolome of patients with IBS who
were on a low FODMAP diet.3 Although
low FODMAP intake reduces GI symp-
toms in almost 75% of patients with IBS,
the effects of this diet on the intestinal
microbiota might be disadvantageous in
the long run.
Combining these observations with the
important role for the intestinal micro-
biota in IBS pathogenesis,4 we report here
faecal microbiota transplantation (FMT)
as an alternative to FODMAP restriction
in patients with IBS. We applied FMT in
12 refractory IBS patients (Rome III cri-
teria) with intermittent diarrhoea
and severe bloating, and mapped the
associated microbiota changes after
therapy 5 6 (see online supplementary file).
In our cohort, the median disease duration
was 14.5 years (5–40) and patients (8/12
female) had undergone at least three con-
ventional treatment attempts prior to
inclusion (see online supplementary table
S1). Consecutive faecal samples were col-
lected from the last seven patients for
microbiome analyses.
In this study nine patients (75%) met the
primary endpoint being: ‘adequate relief of
global IBS symptoms and abdominal bloat-
ing’, 12 weeks after FMT. A significant
reduction in general abdominal discomfort
(−21%), abdominal pain (−26%), bloating
(−35%) and flatulence (−37%) was
reported. The overall quality of life also
improved significantly (+12.9%) (see
online supplementary tables S2 and S3,
figure 1). Responders were followed up and
7/9 (78%) still reported significant relief of
IBS symptoms after a period of 1 year, sug-
gesting long-lasting effects of FMT.
Microbiota analysis showed no commu-
nity differences between patients and
donors and no difference in microbial dis-
similarity between patient–donor respon-
ders and non-responder pairs at baseline.
However, we observed a trend of higher
Streptococcus counts in donors compared
with patients (uncorrected p=0.011) and
successful donors tended to have higher
baseline counts of Streptococcus compared
with non-successful donors (figure 2).
Interestingly, we also observed a trend of
higher enrichment potential in responders
compared with non-responders (figure 2).
In line with earlier observations in IBD,
the median number of successfully trans-
ferred phylotypes was also higher in
responders (n=6) versus non-responders
(n=2.5) (not significant).7
With this open-label FMT study in
patients with IBS, we found a similar
response rate as for the low-FODMAP
diet. Interestingly, positive effects on
IBS-related symptoms seem to be linked
to changes in the intestinal microbiota
due to FMT. This study suggests FMTas a
possible treatment option for IBS and sup-
ports correlations between abnormalities
in the intestinal microbiota and IBS.
The main limitation of our study is its
design as an open-label trial. Of note,
however, placebo response rates in similar
IBS patient cohorts are reported to be
approximately 37.5%, which is consider-
ably lower than the response rate of 75%
that we report here.8 Nonetheless,
double-blind, placebo-controlled trials,
addressing also microbial changes, are
necessary to provide clear answers
about the applicability of FMT in IBS
and are currently on-going both in our
centre (NCT02299973) and elsewhere
(NCT02092402; NCT02154867).
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Figure 1 Changes in specific IBS-related symptoms at week 12 post-FMT. Lines in green represent responders to the FMT, lines in red represent
non-responders. Wilcoxon’s signed ranks test. FMT, faecal microbiota transplantation.
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Figure 2 Baseline microbial differences between donors and patients and microbial differences according to the response to treatment. (A) The
observed tendency for higher Streptococcus counts at baseline in donors compared with patients (uncorrected p=0.011). (B) The trend for higher
baseline counts of Streptococcus in successful donors compared with non-successful donors. (C) The differences in delta richness (donor minus
patient) values between patients with IBS responding to the FMT versus non-responders (Chao1 richness: p=0.095). FMT, faecal microbiota
transplantation.
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